Bioasis Announces Investor Relations Service Agreement with Stern IR

GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3  platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern IR”) to provide strategic advisory services, enhance and execute the Company’s investor relations program and support ongoing efforts to expand visibility within the North American investment community in compliance with regulatory guidelines.

“In an increasingly complex and diverse marketplace, an effective investor relations program is essential to communicate our growth strategy, differentiate Bioasis in the eyes of investors and position our company for long-term success,” said Catherine London, executive vice president, investor relations and corporate communications, Bioasis. “The Stern IR team of investor relations professionals has a proven track record of success in connecting biotech companies with the broader investment community. We look forward to working with them to expand our company visibility among prospective investors in the months ahead.”

Under the terms of the agreement, Stern IR will provide comprehensive investor relations services for an initial six-month term, commencing Oct. 4, 2018, at an anticipated cost of $90,000, payable at the rate of $15,000 per month. The agreement is subject to acceptance by the TSX Venture Exchange.

“There are many therapies that have the potential to make a world of difference in the treatment of CNS diseases, but too many of them cannot be delivered at therapeutic levels to their targets in the brain. We are very energized by the potential that our xB3 platform technology has shown to deliver many of these treatments across the BBB for the treatment of brain cancers and other neurological disorders. The safe delivery of treatments to the brain could be game changers for those afflicted with neurological disorders,” said Mark Day, Ph.D., director, president and chief executive officer, Bioasis. “We look forward to the Stern IR team helping us raise investor and industry awareness of Bioasis and our technology.”

On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director and President & Chief Executive Officer

Stern IR is a premier investor relations firm that provides consulting services to entrepreneurial healthcare and biotechnology companies. Since its inception in 1998, Stern IR has worked with more than 200 biotechnology, specialty pharmaceuticals, devices, and healthcare services companies in all stages of development and across all therapeutic areas. None of Stern IR nor any of its directors and officers own any securities of Bioasis. Stern IR is based in New York City. For more information, please visit

ABOUT Bioasis
Bioasis Technologies, Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements regarding the anticipated completion of a proposed private placement, the Company’s intended use of proceeds of the private placement, along with other statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”


Bioasis Technologies, Inc.
Catherine London, +1-917-763-2709